key: cord-0825726-5j1pce5e
authors: Rozo, Nathaly; Valencia, Diana; Newton, Suzanne M.; Avila, Greace; Gonzalez, Maritza A.; Sancken, Christina L.; Burkel, Veronica K.; Ellington, Sascha R.; Gilboa, Suzanne M.; Rao, Carol Y.; Azziz‐Baumgartner, Eduardo; Ospina, Martha L.; Prieto, Franklyn E.; Tong, Van T.
title: Severity of illness by pregnancy status among laboratory‐confirmed SARS‐CoV‐2 infections occurring in reproductive‐aged women in Colombia
date: 2021-09-01
journal: Paediatr Perinat Epidemiol
DOI: 10.1111/ppe.12808
sha: 1aa308092dd749d9f7edd7665babf920516d58e9
doc_id: 825726
cord_uid: 5j1pce5e

BACKGROUND: Multiple studies have described increased risk of severe coronavirus disease (COVID‐19) among pregnant women compared to nonpregnant women. The risk in middle‐income countries where the distributions of age groups and preexisting conditions may differ is less known. OBJECTIVES: To determine whether pregnant women with SARS‐CoV‐2 infection are at increased risk for severe COVID‐19 compared to nonpregnant women in Colombia. METHODS: We analysed national surveillance data from Colombia, of women aged 15–44 years with laboratory‐confirmed infection with SARS‐CoV‐2 by molecular or antigen testing, from 6 March 2020 to 12 December 2020. An enhanced follow‐up of pregnant women with COVID‐19 was established to monitor pregnancy and birth outcomes. RESULTS: Of 371,363 women aged 15–44 years with laboratory‐confirmed SARS‐CoV‐2 infection, 1.5% (n = 5614) were reported as pregnant; among those, 2610 (46.5%) were considered a complete pregnancy for reporting purposes at the time of analysis. Hospitalisation (23.9%) and death (1.3%) occurred more frequently among pregnant symptomatic women compared to nonpregnant symptomatic women (2.9% and 0.3%, respectively). Compared to nonpregnant symptomatic women, pregnant symptomatic women were at increased risk of hospitalisation (adjusted risk ratio (RR) 2.19, 95% confidence interval (CI) 2.07, 2.32) and death (RR 1.82, 95% CI 1.60, 2.07), after adjusting for age, type of health insurance and presence of certain underlying medical conditions. Among complete pregnancies, 55 (2.1%) were pregnancy losses, 72 (2.8%) resulted in term low birthweight infants and 375 (14.4%) were preterm deliveries. CONCLUSIONS: Although pregnant women were infrequently reported with laboratory‐confirmed SARS‐CoV‐2 infection, pregnant symptomatic women with COVID‐19 were at increased risk for hospitalisation and death compared to nonpregnant symptomatic women. Almost all infections we reported on were third‐trimester infections; ongoing follow‐up is needed to determine pregnancy outcomes among women infected earlier in pregnancy. Healthcare providers should counsel pregnant women about preventive measures to protect from SARS‐CoV‐2 infection and when to seek care.

Studies from multiple countries have described increased risk of severe illness of coronavirus disease 2019 in pregnant people compared to nonpregnant people, [1] [2] [3] and pregnant people with COVID-19 are at increased risk of adverse pregnancy outcomes, such as preterm birth and stillbirth. 2, 4 However, the risk in pregnancy and the overall burden is less known in middle-income countries, where the distribution of age groups and preexisting conditions as well as standards of care are different. 5 The first COVID-19 laboratory-confirmed case in Colombia was identified on 6 March 2020. As of 10 May 2021, Colombia has reported 3,002,758 confirmed cases of COVID-19 and 77,854 COVID-19-related deaths, among an estimated total population of 48 million. 6 In 2019, there were 650,000 births in Colombia, with the age distribution as 47% for 15-to 24-year-olds and 41% for 25-to 34-year-olds. 7 The majority of pregnant people attend prenatal care, regardless of socioeconomic status, with almost 80% initiating prenatal care in the first trimester of pregnancy. 8 The burden and characteristics of pregnant people with SARS-CoV-2, the virus that causes COVID-19, infection and impact on severity of illness and adverse outcomes in Colombia have yet to be described.

Colombia has a passive national surveillance system (known as Sivigila) for over 100 public health reportable conditions. In February 2020, Colombia's Instituto Nacional de Salud (INS) published guidelines for COVID-19 surveillance, 9 and Sivigila rapidly created a case report form and trained local health authorities on the identification and mandatory reporting of COVID-19 daily to INS. The case report form captures whether a woman is pregnant and other information such as symptoms, underlying conditions and markers of illness severity (eg hospitalisation, death). Colombia also established a protocol to conduct enhanced follow-up of pregnant women with COVID-19 and continues to monitor pregnancy and birth outcomes among this cohort to help avoid complications, disabilities and death in pregnant women and newborns.

We conducted a secondary data analysis to describe the overall burden and characteristics of women aged 15-44 years with laboratory-confirmed SARS-CoV-2 infection by pregnancy status and assess risk of severe illness among pregnant women compared to nonpregnant women reported to the national surveillance system in Colombia. Among those women with a single gestation pregnancy, SARS-CoV-2 infection and sufficient time for a complete pregnancy, we report on birth outcomes. These findings can help contribute to our understanding of the impact of COVID-19 on severity of illness during pregnancy and adverse outcomes, particularly in a middleincome setting, and can be used to inform local efforts for public health and clinical decision-making. 

Pregnant symptomatic women with COVID-19 were at increased risk for hospitalisation and death compared to nonpregnant symptomatic women in Colombia. Preliminary findings suggest that pregnancy loss and preterm birth, mostly among third-trimester infections, do not appear higher than pre-pandemic rates.

breathing, odynophagia, fatigue, loss of taste or smell and meet at least one of the following conditions: belong to at least one highrisk group, such as healthcare or social worker, or have had close contact with a confirmed or probable case of COVID-19 in the past 14 days or have a positive serologic test specific for IgM antibodies taken 11 days (immunochromatography) or 14 days (ELISA or chemiluminescence) after symptom-onset date. Criteria for a probable death due to COVID-19 include all deaths from severe acute respiratory infection with a clinical picture of unknown aetiology and meeting any of the following conditions mentioned above for probable cases. Criteria for asymptomatic cases include close contact with a confirmed case of COVID-19 and no symptoms have oc- testing results, birth records to obtain pregnancy and birth outcome, surveillance for maternal morbidity complications 13 and death records to identify maternal or infant deaths.

The exposure for this analysis is laboratory-confirmed SARS-CoV 

This analysis examines hospitalisation and death among women of reproductive age with laboratory-confirmed SARS-CoV-2 infection to determine severity of illness. Since some pregnancies are ongoing, we examined birth and infant outcomes by trimester of infection among all pregnant women with SARS-CoV-2 infection by restricting the analysis to pregnancies that could have the potential for duration of 42 weeks by the end of the study period (December 12, 2020), as well as to women with a single gestation pregnancy. We excluded all pregnancies for which a hypothetical duration of 42 weeks would end after 12 December 2020, regardless of whether the pregnancy outcomes occurred prior to that date, to avoid overestimating frequency of pregnancy loss and preterm birth. Among the same subset of pregnancies, we also report on severe maternal morbidity complication (ie a severe life-threatening obstetric pregnancy complication during the pregnancy, delivery or within 42 days of delivery). 15

The analysis was limited to laboratory-confirmed SARS-CoV-2 infections among women aged 15-44 years reported to INS from 6 March to 12 December 2020. Given the difference in magnitude of cases by pregnancy status, we examined weekly number of cases by pregnancy status, using absolute frequency and logarithmic scale. We also report number of infections by department (ie state) in Colombia. To examine severity of illness, we restricted the analysis to symptomatic and SARS-CoV-2-positive women to focus on the complications related to COVID-19, but we also present the data for the entire cohort in a supplemental table. Unadjusted and adjusted (aRR) risk ratios and 95% confidence intervals (CI) were calculated using log-binomial regression to assess risk of hospitalisation and death for pregnant women compared to nonpregnant women.

Overall and stratified risk ratios were adjusted for continuous age (in years), type of health insurance and presence of obesity, asthma, diabetes or cardiovascular disease. Analyses were conducted in STATA and SAS ® 9.4 software. 16, 17 

Outcome measures and covariates had no missing information, except for type of health insurance which was missing for 6.5% of women in our study population. Imputation of 40 data sets was employed for the analysis of risk factors for severe COVID-19 among women with SARS-CoV-2 infection using the fully conditional specification method. Following imputation, regression models were computed using the imputed data sets. Results were combined, taking the variation between the results of the imputed data sets into account. Frequencies presented for type of health insurance in Tables 2 and S1 are from the first imputed data set.

Per Colombian resolution 08430 of 1993, the study is considered minimal risk, since retrospective documentary techniques and methods were used and no intervention or intentional modification of the biological, physiological, psychological or social variables were carried out. 18 This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy. 19 Table 2 ). Risk of hospitalisation and death was higher for pregnant women in all age groups compared to nonpregnant women.

Risk of hospitalisation was higher for pregnant women within all insurance groups, and risk of death was higher among pregnant women with employer-based or subsidised health insurance compared to nonpregnant women. Pregnant women with obesity, asthma, diabetes and cardiovascular disease were at an increased risk for hospitalisation compared to nonpregnant women with these medical conditions. Pregnant women with asthma were also at greater risk for death compared to nonpregnant women with asthma. These associations held true for all SARS-CoV-2-positive pregnant women compared to SARS-CoV-2-positive nonpregnant women (Table S1) . (Table 3) ; 55 (2.1%) had pregnancy losses reported. After excluding pregnancy losses, 2.8% of infants were reported to be term low birthweight and 14.7% of infants were preterm. A higher frequency of preterm deliveries was reported in symptomatic compared to asymptomatic women (15.7% vs 11.4%) ( Table S2 ). In the maternal morbidity surveillance, 14.2% of pregnant women with SARS-CoV-2 infection presented with severe life-threatening complications during the pregnancy, and frequency by symptom status was similar (Table S2 ).

Using national population-based surveillance data from Colombia in 2020, pregnant women with laboratory-confirmed SARS-CoV-2 infection had an increased risk of COVID-19 hospitalisation and death.

Stratified analyses reveal an increased risk for hospitalisation for all age groups, all types of health insurance and obesity, asthma, diabetes and F I G U R E 2 Counts of laboratoryconfirmed SARS-CoV-2 infections among women of reproductive age (WRA) by department, Colombia TA B L E 1 Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2 infections by pregnancy status, 

Strengths of this report include that the data come from national surveillance, representing Colombia's diverse population. By including women with positive antigen testing which has high specificity and is more easily accessible outside of a hospital setting, we likely captured more mild cases making our study population more representative of pregnant women with acute infection. In addition, we excluded 8% of pregnancies with reported outcomes as they did not meet our criteria of the 42-week observation period by 12 December 2020. This was done to avoid overestimating frequency of pregnancy loss and preterm birth as those with pregnancies that were still ongoing have yet to be reported. This study provides further evidence from an additional setting, in particular a middle-income country with different population characteristics and transmission patterns, that pregnant women are at increased risk of severe illness of COVID-19.

There are some limitations to note. First, only 1% of COVID-19 patients were indicated as being pregnant; based on national data, it is expected that approximately 4% of women of reproductive age are pregnant at a given time. 7 Although INS contacted local providers regarding the enhanced surveillance of pregnant women, pregnancy status may not have been as completely ascertained as possible, introducing potential misclassification. Given that pregnant women have frequent encounters for care and there might be heightened monitoring, pregnant women who were asymptomatic or who had more mild disease may be detected over nonpregnant women. However, we attempted to address this issue by limiting analysis of illness severity to symptomatic individuals. Second, hospitalisation results should be interpreted with caution due to pregnant women being more likely to be hospitalised out of an abundance of caution. Third, outcomes were missing for 13% of pregnant women with infections that met the inclusion criteria to be included in this report. However, we included them in our denominator when calculating birth and infant outcomes, but these estimates are preliminary and should be interpreted with caution. Fourth, preterm perhaps because of the enhanced follow-up of these cases or because they were under medical care. Sixth, differences in findings from other studies could be due to differences in testing and reporting of cases, lower number of cases to detect differences for rare outcomes and differences in healthcare systems to manage and treat persons with severe COVID-19 illness.

Pregnant women in Colombia with laboratory-confirmed SARS- fants, and the surveillance system will provide useful information to update the guidelines when necessary.

In conclusion, the findings in this report provide evidence of the increased risk of severe illness of COVID-19 among pregnant women in Colombia. As most pregnancies are still ongoing, continued longitudinal surveillance of pregnancy and infant outcomes are needed.

Colombia's public health surveillance incorporated monitoring of pregnant women rapidly, which provided information for clinical decision-making. Medical and public healthcare teams need to consider known risk factors for severe illness such as increased maternal age and underlying medical conditions when counselling about preventive measures for COVID-19.

The findings and conclusions of this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. 

Update: characteristics of symptomatic women of reproductive age with laboratoryconfirmed SARS-CoV-2 infection by pregnancy status -United States

Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis

Pregnant women with SARS-CoV-2 infection are at higher risk of death and pneumonia: propensity score matched analysis of a nationwide prospective cohort (COV19Mx)

The impact of COVID-19 on pregnancy outcomes: a systematic review and metaanalysis

Perinatal COVID-19 in Latin America TT -COVID-19 perinatal en América Latina

COVID-19 en Colombia

Datos de nacimientos en Colombia

Circular No.005 de 2020-Directrices detencion temprana Control Coronavirus

Instructivo para la Vigilancia en Salud Pública Intensificada de Infección Respiratoria Aguda y la Enfermedad Asociada al Nuevo Coronavirus

Protocolo de Vigilancia en Salud Pública -Morbilidad Materna Extrema

Interim Guidance for Antigen Testing for SARS-CoV-2

Maternal near miss -towards a standard tool for monitoring quality of maternal health care

StataCorp. Stata Statistical Software: Release 17. StataCorp LLC

4 Interface to ADABAS: Reference

Resolucion Numero 8430 de 1993. https:// www.hospi talsa npedro.org/image s/Comite_Inves tigac ion/Resol ucion_8430_de_1993

part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 3501 et seq

Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis

Recién Nacidos y para la Lactancia Materna, en el Contexto de la Pandemia de COVID-19 en Colombia

Severity of illness by pregnancy status among laboratoryconfirmed SARS-CoV-2 infections occurring in reproductiveaged women in Colombia

We thank the following persons for their contributions to this pro-